77.29MMarket Cap-1340P/E (TTM)
1.250High1.080Low402.08KVolume1.090Open1.090Pre Close476.27KTurnover0.64%Turnover RatioLossP/E (Static)63.35MShares3.24952wk High3.05P/B76.68MFloat Cap0.45052wk Low--Dividend TTM62.86MShs Float31.690Historical High--Div YieldTTM15.60%Amplitude0.450Historical Low1.184Avg Price1Lot Size
Cue Biopharma Stock Forum
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
Cue Biopharma presented updated Phase 1 trial data for CUE-101 and CUE-102 at SITC 2024. CUE-101 combined with KEYTRUDA showed impressive results in head and neck cancer patients, achieving a 46% objective response rate and 91.3% 12-month overall survival. The median overall survival reached 21.8 m...
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
📊⚡️📊
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.
An oral presentation by Dr. Christine Chung will discuss a ph...
No comment yet